138 related articles for article (PubMed ID: 36040238)
21. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Vitale MG; Bruni A; Lohr F; Procopio G; Caffo O; Nole F; Morelli F; Baier S; Buttigliero C; Ciammella P; Timon G; Fantinel E; Carlinfante G; Berselli A; Pinto C
Eur Urol; 2022 Mar; 81(3):274-282. PubMed ID: 34602312
[TBL] [Abstract][Full Text] [Related]
22. A case of primary malignant melanoma of the esophagogastric junction with abscopal effect after nivolumab administration.
Yamaguchi T; Fushida S; Kinoshita J; Saito H; Shimada M; Terai S; Moriyama H; Okamoto K; Nakamura K; Ninomiya I; Inaki N
Surg Case Rep; 2021 Dec; 7(1):253. PubMed ID: 34882298
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
24. Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications.
Soule E; Bandyk M; Matteo J
Cryobiology; 2018 Jun; 82():22-26. PubMed ID: 29680230
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
26. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
27. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.
Tubin S; Popper HH; Brcic L
Radiat Oncol; 2019 Jan; 14(1):21. PubMed ID: 30696472
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
29. Abscopal effect in maxillary sinus cancer: Insights from two case reports and a literature review.
Sakai A; Ebisumoto K; Iijima H; Yamauchi M; Maki D; Fukuzawa T; Okami K
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1994. PubMed ID: 38351554
[TBL] [Abstract][Full Text] [Related]
30. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
31. Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.
Gim G; Kim Y; Park Y; Kim MJ; Nam M; Yang W; Duarte SE; Jung CM; Vagia E; Viveiros P; Chae YK
Oncologist; 2022 Jul; 27(7):525-531. PubMed ID: 35640145
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report.
Guidi A; Violati M; Blasi M; Ferrari E; Luciani A; Codecà C; Ferrari D
Tumori; 2020 Dec; 106(6):NP23-NP28. PubMed ID: 32851941
[TBL] [Abstract][Full Text] [Related]
33. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
Noji R; Kano Y; Hirai H; Onishi I; Nishii N; Yoshimura R; Miyake S; Ikeda S; Harada H
Oral Oncol; 2022 Jan; 124():105666. PubMed ID: 34896892
[TBL] [Abstract][Full Text] [Related]
34. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition.
Trommer M; Yeo SY; Persigehl T; Bunck A; Grüll H; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Herter JM; Celik E; Marnitz S; Baues C
Front Pharmacol; 2019; 10():511. PubMed ID: 31156434
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis.
Zhang X; Zhang Y; Liu Y; Yang Y; Dong P; He L; Zhou F
Transl Androl Urol; 2021 Nov; 10(11):4304-4312. PubMed ID: 34984195
[TBL] [Abstract][Full Text] [Related]
36. Differential abscopal effect in extracranial and intracranial lesions after radiotherapy alone for vertebral bone metastasis of unknown primary: a case report.
Ishikawa Y; Umezawa R; Yamamoto T; Takahashi N; Takeda K; Suzuki Y; Jingu K
J Med Case Rep; 2022 Mar; 16(1):94. PubMed ID: 35248152
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy-induced abscopal effect on the metastatic carcinoma of unknown primary origin: a case report and literature review.
Guo Z; Zhou J; Guo H; Liu LK
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4634-4637. PubMed ID: 35856353
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression.
Lauber K; Dunn L
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():352-363. PubMed ID: 31099687
[TBL] [Abstract][Full Text] [Related]
39. Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
Sari SY; Yilmaz MT; Aktas BY; Aksoy S; Gullu I; Cengiz M; Ozyigit G; Yazici G
Oral Oncol; 2022 Jan; 124():105658. PubMed ID: 34883400
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
